PRCT — PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $76.4 million, up 12% year-over-year.
• U.S. Revenue: $66.6 million, reflecting 10% growth.
• Procedures Completed: Approximately 12,200, representing a 69% increase year-over-year.
• Handpieces Sold: 9,400 units with an average selling price (ASP) of $3,340, a 5% sequential increase.
• Gross Margin: 60.6%, down from 64% in Q4 2024, impacted by lower consumable revenue and a one-time field action.
• Net Loss: $29.8 million, compared to a loss of $18.9 million in Q4 2024.
• Adjusted EBITDA: Loss of $19 million, worsening from a loss of $10.3 million year-over-year.
• Cash Position: $285 million as of December 31, 2025.

2. Strategic Updates and Business Highlights

• Leadership Changes: Larry Wood emphasized a shift in operational focus towards increasing procedure volume, expanding margins, and achieving profitability.
• Sales Force Realignment: A new integrated regional structure was established, aligning clinical and sales functions under common leadership to enhance accountability and customer success.
• Launch Team Formation: A dedicated team was created to improve new system placements and accelerate customer activation, aiming for standardized and successful launches.
• Pricing Discipline: The company eliminated bulk purchase discounts, leading to improved ASPs and aligning handpiece sales more closely with procedure volumes.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $390 million and $410 million, indicating growth of 27% to 33%.
• U.S. Procedures Forecast: Anticipated to be between 60,000 and 64,000, representing growth of approximately 39% to 48%.
• ASP Projection: Expected to rise to $3,500 in 2026.
• Gross Margin Expectation: Projected to be around 65% for 2026, factoring in increased tariff expenses.
• Q1 2026 Revenue Guidance: Expected between $79 million and $82 million, reflecting growth of 14% to 19%.

4. Bad News, Challenges, or Points of Concern

• Revenue Shortfall: Q4 revenue was lower than expected due to changes in customer ordering behavior following the elimination of bulk discounts.
• Gross Margin Decline: The gross margin fell short of guidance due to lower consumable sales and a one-time field action impacting profitability.
• Sales Force Disruption: The realignment of the sales force may cause short-term disruptions as relationships with customers need to be rebuilt.
• Market Competition: Concerns regarding the impact of Prostatic Artery Embolization (PAE) procedures on Aquablation's market share, as more urologists adopt PAE.

5. Notable Q&A Insights

• Customer Behavior: Larry Wood noted that the previous bulk purchase incentives had led to distorted ordering patterns, which have now been corrected to align with actual procedure volumes.
• Confidence in 1:1 Ratio: Management expressed confidence in achieving a 1:1 ratio of handpieces sold to procedures completed in 2026, despite historical discrepancies.
• Field Action Impact: The recent voluntary field action was clarified as a one-time event with no ongoing implications for product safety or future sales.
• Market Development: There is a commitment to enhancing patient and clinician education regarding Aquablation's benefits, which has been historically lacking.
• Sales Force Stability: The team remains stable, with no significant attrition reported, although the restructuring requires time for adaptation and relationship rebuilding.

Overall, while PROCEPT BioRobotics faced challenges in Q4 2025, the strategic initiatives and forward guidance indicate a focus on long-term growth and profitability.